USPTO Patent Grants - Organic Chemistry (C07D)

Crystalline Salts of Plasma Kallikrein Inhibitor Patent

USPTO granted patent US12590069B2 to BioCryst Pharmaceuticals, Inc. covering crystalline salts of a plasma kallikrein inhibitor (Compound I), methods of preparation, pharmaceutical preparations, and methods of treatment. The patent (30 claims) names inventors Yahya El-Kattan and Yarlagadda S. Babu, with an August 28, 2025 filing date. This is a routine patent grant establishing intellectual property protection with no new regulatory compliance obligations.

Thyromimetics Patent - Autobahn Therapeutics

USPTO granted patent US12590072B2 to Autobahn Therapeutics, Inc. covering thyromimetic compounds for treating neurodegenerative disorders and fibrotic diseases. The patent (20 claims) names inventors Thomas von Geldern and Bradley Backes, with original filing date June 17, 2021. This is a routine patent grant notice with no compliance obligations.

Crystalline salts of plasma kallikrein inhibitor patent grant

USPTO granted BioCryst Pharmaceuticals, Inc. Patent US12590068B2 covering crystalline salts of a plasma kallikrein inhibitor (Compound I), methods of preparation, and related pharmaceutical preparations. Inventors: Yahya El-Kattan and Yarlagadda S. Babu. The patent contains 30 claims and 3 CPC classifications (C07D 231/14, A61K 9/0029, C07B 2200/13).

Adamantane derivatives as inhibitors of focal adhesion kinase

USPTO granted patent US12590070B2 to Samjin Pharmaceutical Co., Ltd. on March 31, 2026, covering novel adamantane derivatives as inhibitors of focal adhesion kinase (FAK) for pharmaceutical use. The patent includes 17 allowed claims and covers compounds, salts, stereoisomers, and pharmaceutical compositions. The invention is classified under CPC codes including C07D 239/48, C07D 401/12, and A61P 35/00 (antineoplastic agents).

Hydrazone derivative with aryl-substituted terminal amine group and use thereof

USPTO granted Patent No. US12590071B2 to Korea Institute of Science and Technology on March 31, 2026, covering hydrazone derivatives where the terminal amine group is substituted with aryl or heteroaryl groups. The patent includes 14 claims relating to compounds represented by Formulas 3 and 4, and methods of making these compounds. The patent relates to heterocyclic organic chemistry with potential pharmaceutical applications.

Process for preparation of macrocyclic chelant and metal complexes

USPTO granted patent US12590073B2 to Biophore India Pharmaceuticals Pvt. Ltd. for an improved process preparing macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid and its gadolinium/calcium metal complexes with purity exceeding 99.0% by HPLC. The patent names inventors Manik Reddy Pullagurla and Jagadeesh Babu Rangisetty, with 9 claims granted.

Method of fixating carbon dioxide to substituted oxazolidinones using MOF technology

USPTO granted patent US12590074B2 to King Fahd University of Petroleum and Minerals on March 31, 2026. The patent covers a method of fixating carbon dioxide (CO2) to form substituted oxazolidinones using a MIL-68(In)-X metal-organic framework (MOF) catalyst, reacting CO2 with epoxides and aromatic amines. The patent contains 20 claims and application number 18329092.

Process for the production of levetiracetam

USPTO granted Patent US12590059B2 to Suzhou BrightHope Pharmatech Co., Ltd. for a process to produce levetiracetam via crystallization in aqueous solution, resulting in a product containing no residual organic solvent. The patent lists 4 inventors (Songzhou Hu, Lijun Deng, Wen Yu, Zhen Song) and contains 13 claims under classification C07D 207/27.

Levorphanol prodrugs and processes for making and using them

The USPTO granted Patent US12590065B2 to Zevra Therapeutics, Inc. covering novel levorphanol prodrug compositions formed by chemically conjugating oxoacids, polyethylene glycols, or vitamin compounds to levorphanol. The patent includes claims to the compositions and methods of making and using them.

Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof

USPTO granted Patent US12590066B2 to Korea Institute of Science and Technology for novel fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds. The patent includes 20 claims and names inventors Ae Nim Pae, Yun Kyung Kim, Sang Min Lim, Sungsu Lim, Haeun Lee, Woo Seung Son, and Hye Yeon Lee. The compounds have potential pharmaceutical applications.

USPTO Patent Grant: Daprodustat Crystal Form M Preparation and Use

The USPTO has granted patent US12583823B2 for a specific crystal form (crystal form M) of the drug daprodustat, a proline hydroxylase inhibitor. The patent covers the preparation method and use of this crystal form, which exhibits improved stability and solubility characteristics.

USPTO Patent Grant: Light-Emitting Element with Long Lifetime

The USPTO has granted a patent (US12588408B2) to Semiconductor Energy Laboratory Co., Ltd. for a novel light-emitting element. The patent describes an element with a long lifetime and high efficiency, utilizing specific organic acceptor and host materials in its electron-transport layers.

USPTO Patent Grant for PCSK9 Inhibitors

The USPTO has granted a patent (US12584120B2) to AstraZeneca AB for novel PCSK9 inhibitors and methods of use. The patent covers specific heteroaryl compounds that bind the PCSK9 protein, aiming to advance treatments for conditions related to cholesterol regulation.

Biomaterial with functionalized tyrosine, preparation method, pharmaceutical composition

The USPTO has granted a patent (US12583818B2) for a method to prepare a biomaterial with selectively functionalized tyrosine and a pharmaceutical composition containing it. This innovation aims to improve the efficacy of biomaterial drugs by ensuring selective coupling to tyrosine without affecting other amino acids or the biomaterial's inherent activity.

USPTO Patent Grant: Chemokine CXCR4 Receptor Modulators

The USPTO has granted a patent to Emory University for chemokine CXCR4 receptor modulators and their uses. The patent covers compounds and pharmaceutical compositions that can be used for managing various conditions including viral infections, abnormal cellular proliferation, and cancer.

USPTO Patent Grant: PSMA Imaging Agents

The United States Patent and Trademark Office (USPTO) has granted patent US12583887B2 to Siemens Medical Solutions USA, Inc. for PSMA imaging agents. The patent covers compounds and methods for imaging prostate-specific membrane antigen (PSMA), suitable for PET and SPECT imaging.

USPTO Grants PRMT5 Inhibitors Patent to Merck Sharp & Dohme

The USPTO has granted a new patent (US12583871B2) to Merck Sharp & Dohme LLC for PRMT5 inhibitors. The patent covers compounds and methods for treating conditions such as cancer, sickle cell, and hereditary persistence of foetal hemoglobin.

Azaheteroaryl Compound Patent Granted

The USPTO has granted patent US12583870B2 to SHANGHAI BLUERAY BIOPHARMA CO., LTD. for an azaheteroaryl compound and its preparation method. This patent covers compounds and compositions for treating diseases related to EED protein and PRC2 protein complex mechanisms.

A2A Receptor Antagonist Salt and Crystal Forms

The USPTO has granted patent US12583869B2 for a salt form and crystal form of an adenosine A2A receptor antagonist, along with its preparation method. The patent, assigned to CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD., also covers the application of these forms in preparing medicine for A2A receptor-related diseases.

USPTO Patent Grant: JAK Inhibitors Synthesis Methods

The USPTO has granted patent US12583868B2 for novel JAK inhibitors and methods for their synthesis and use, assigned to Galderma Holding SA. The patent covers compounds with formula (I) and their application in treating various diseases.

USPTO Patent Grant: Pyridone Derivative Crystal Form

The USPTO has granted a patent to Jiangxi Caishi Pharmaceutical Technology Co., Ltd. for a novel pyridone derivative crystal form and its preparation method. This patent covers specific crystal forms and their application in treating influenza, potentially offering improved efficacy and bioavailability.

USPTO Patent Grant: IAP Antagonists for Cancer Treatment

The USPTO has granted a patent (US12583866B2) to BeOne Medicines I GmbH for novel pyrido[2,3-b][1,4]oxazine or tetrahydropyrido[2,3-b][1,4]oxazepine derivatives. These compounds act as antagonists of Inhibitors of Apoptosis Proteins (IAPs) and are intended for use in treating cancer by inducing or sensitizing cells to apoptotic cell death.

Biologically Active Taxane Analogs and Oral Treatment Methods - Patent Granted

The USPTO has granted a patent (US12583865B2) to Tapestry Pharmaceuticals, Inc. for biologically active taxane analogs and methods of oral treatment for cancer. The patent covers novel chemical compounds, compositions, manufacturing methods, and combinations with other therapeutic agents.

Organic EL Device with Different Host Materials

The USPTO has granted a patent for an organic electroluminescent (EL) device. The patent describes a device with two emitting layers, each containing a different host material and a compound that emits fluorescence with a main peak wavelength of 500 nm or less. The patent specifies a condition for the triplet energy of the host materials.

USPTO Grants Patent for Nanoporous Material for Ion Channels

The USPTO has granted a new patent (US12583863B2) to the University of Wyoming for a synthetically modifiable ion channel material. This material, a nanoporous structure with controlled electronic and ion transport properties, mimics natural zeolites and MOFs.

USPTO Patent Grant for API Crystalline Form Preparation

The USPTO has granted patent US12583860B2 to Apotex Inc. for processes to prepare multicomponent crystalline forms of active pharmaceutical ingredients using solvent vapour. The patent covers methods involving mixing a solid API with a liquid or solid pharmaceutically acceptable entity in the presence of solvent vapour, utilizing standard rotary apparatus.

USPTO Patent Grant US12583859B2 for PRMT5 Inhibitors

The USPTO has granted patent US12583859B2 to the California Institute of Technology for PRMT5 inhibitors. The patent covers compounds and methods useful in treating cancers and other diseases.

Genentech, Inc. Granted Patent for TDO2 Inhibitors

The USPTO has granted Genentech, Inc. patent US12583858B2 for TDO2 inhibitors. These inhibitors are useful for modulating tryptophan 2,3 dioxygenase activity, treating immunosuppression, and enhancing anti-cancer treatments. The patent was filed on October 12, 2020.

USPTO Patent US12583857B2 for Anti-liferative Agents

The USPTO has granted patent US12583857B2 for anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines. The patent was granted to PHEON THERAPEUTICS LTD and covers compounds useful as medicaments, particularly as anti-proliferative agents.

Amgen KRAS G12C Inhibitors Patent Granted

The USPTO has granted Amgen Inc. a patent (US12583854B2) for KRAS G12C inhibitors and methods of using them to treat cancers. The patent covers compositions and methods for treating pancreatic, colorectal, and lung cancers.

USPTO Patent Grant for BCL-2 Inhibitors

The USPTO has granted a patent (US12583853B2) to Newave Pharmaceutical Inc. for 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors. These compounds are intended for the treatment of neoplastic and autoimmune diseases.

USPTO Patent Grant: Heterocycle Derivative for Hair Loss Therapy

The USPTO has granted patent US12583852B2 for a novel heterocycle derivative, assigned to JW PHARMACEUTICAL CORPORATION. This patent covers compounds effective for the therapy and prevention of hair loss, including androgenic alopecia and alopecia areata.

USPTO Patent Grant: Pyrazine Derivatives for Pest Control

The USPTO has granted patent US12583851B2 to Elanco Animal Health GmbH for novel heteroaryl-substituted pyrazine derivatives. These compounds are intended for controlling animal pests, arthropods, insects in plant protection, and ectoparasites on animals.

USPTO Patent US12583849B2 for KCNT1 Inhibitors

The USPTO has granted patent US12583849B2 to PRAXIS PRECISION MEDICINES, INC. for KCNT1 inhibitors and methods of use. This patent covers compounds and compositions for treating neurological diseases, conditions related to excessive neuronal excitability, and gain-of-function mutations in genes like KCNT1.

USPTO Patent US12583848B2: Isoxazole Derivatives for Viral Infections

The USPTO has granted patent US12583848B2 to Universitätsklinikum Jena for isoxazole-3-carboxamide derivatives used in treating viral infections. The patent describes compounds effective against various viruses, including resistant strains, with low induction of cytochrome P4503A4.

USPTO Patent Grant for Fluorinated Pyrimidine Compound Production

The USPTO has granted a patent (US12583847B2) to UNIMATEC CO., LTD. for a fluorinated pyrimidine compound and its production method. The patent covers specific chemical structures and synthesis processes, with a filing date of March 16, 2022.

USPTO Patent Grant: Benzopyran Derivatives as CRAC Inhibitors

The USPTO has granted a patent (US12583846B2) for benzopyran derivatives identified as CRAC inhibitors. The patent, filed on September 25, 2020, covers compounds represented by a specific formula, isomers, or pharmaceutically acceptable salts thereof, and their application in preparing CRAC inhibitors.

USPTO Patent Grant for Trinucleotide Repeat Disease Treatment

The USPTO has granted a patent (US12583845B2) to The Research Foundation for The State University of New York for compositions and methods to treat diseases involving trinucleotide repeats. The patent covers novel compounds and synthesis processes aimed at inhibiting microsatellite promoted expression of deleterious expansions.

USPTO Patent Grant US12583844B2: Hydantoin MMP Inhibitors

The USPTO has granted patent US12583844B2 to Foresee Pharmaceuticals USA, Inc. for hydantoin-based compounds that act as inhibitors of matrix metalloproteinases (MMPs), particularly MMP-12. The patent covers compositions and methods for treating various diseases mediated by MMP-12.

USPTO Patent Grant for Insomnia and Depression Compound

The USPTO has granted a patent (US12583841B2) to Breakthrough Pharmaceuticals Inc. for a tetrahydropyrrolocyclic compound and its application in preparing drugs to treat insomnia and depression by targeting the selective orexin-2 receptor. The patent was filed on January 27, 2022, and granted on March 24, 2026.

USPTO Patent US12583840B2 for Androgen Receptor Antagonists Preparation

The USPTO has granted patent US12583840B2 to Orion Corporation for a method of preparing androgen receptor antagonists and their intermediates. The patent details a process using a heterogeneous palladium catalyst for the preparation of a specific benzonitrile compound useful in the synthesis of carboxamide-structured androgen receptor antagonists.

USPTO Patent Grant: PD-L1 Antagonist Compound

The USPTO has granted a patent (US12583839B2) to ADLAI NORTYE BIOPHARMA CO., LTD. for a PD-L1 antagonist compound and its pharmaceutical composition. The patent covers compounds of Formula (I) and their use in treating immune-related disorders.

USPTO Patent US12583838B2 for Kinase Inhibitors

The USPTO has granted patent US12583838B2 to Insilico Medicine Hong Kong Limited for kinase inhibitors designed for disease treatment. The patent covers specific compounds and their use in pharmaceutical compositions and methods for treating diseases.

USPTO Patent Grant: Crystal Form of Nitroxoline Prodrug

The USPTO has granted patent US12583835B2 for a crystal form of a nitroxoline prodrug, a pharmaceutical composition containing it, and its preparation and application. The patent, assigned to Jiangsu Yahong Meditech Co., Ltd., describes crystal forms A and B with improved properties for industrial production and drug efficacy compared to nitroxoline.

USPTO Patent Grant: Bacterial Infection Treatment Compound

The USPTO has granted a patent (US12583834B2) for a compound and pharmaceutical composition designed to treat bacterial infections by inhibiting Mfd activity. The patent was filed on February 19, 2021, and is assigned to INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT.

USPTO Patent Grant: Diastereomer-Enriched Odorant Mixture Preparation

The USPTO has granted patent US12583833B2 to Symrise AG for a distillative process to prepare a diastereomer-enriched odorant mixture. The patent covers the process, the enriched mixture, and its use in perfumery to impart or enhance floral odor notes.

USPTO Patent Grant US12583831B2 for Hydrogenation Processes

The USPTO has granted patent US12583831B2 to Archer-Daniels-Midland Company for selective hydrogenation processes and catalysts. The patent covers methods for upgrading impure feedstocks, such as those derived from biomass, to increase the concentration of valuable intermediates like glycolaldehyde and hydroxyacetone.

USPTO Patent Grant: Oxetane Derivative Synthesis Method by Microreactor

The USPTO has granted a patent (US12583830B2) for a microreactor-based synthesis method for oxetane derivatives. The patent, assigned to Changzhou Tronly Advanced Electronic Materials Co., Ltd., details a process that improves efficiency, yield, and safety compared to traditional methods.

USPTO Patent US12583828B2: Aromatic Carbonyl Compounds Preparation Process

The USPTO has granted patent US12583828B2 to BASF SE for a process to prepare aromatic carbonyl compounds. The patent describes a catalytic oxidation method using molecular oxygen, a cobalt(II) salt, and N,N′,N″-trihydroxyisocyanuric acid (THICA).

USPTO Patent Grant: Process for Ethyleneamines and Ethanolamines Manufacture

The USPTO has granted patent US12583827B2 to BASF SE for a new process to manufacture ethyleneamines and ethanolamines. The patent details a two-step process involving the conversion of glycolaldehyde derivatives and an aminating agent, followed by hydrogenation.